Literature DB >> 28921494

Solid-Phase Synthesis of RNA Analogs Containing Phosphorodithioate Linkages.

Xianbin Yang1.   

Abstract

The oligoribonucleotide phosphorodithioate (PS2-RNA) modification uses two sulfur atoms to replace two non-bridging oxygen atoms at an internucleotide phosphorodiester backbone linkage. Like a natural phosphodiester RNA backbone linkage, a PS2-modified backbone linkage is achiral at phosphorus. PS2-RNAs are highly stable to nucleases and several in vitro assays have demonstrated their biological activity. For example, PS2-RNAs silenced mRNA in vitro and bound to protein targets in the form of PS2-aptamers (thioaptamers). Thus, the interest in and promise of PS2-RNAs has drawn attention to synthesizing, isolating, and characterizing these compounds. RNA-thiophosphoramidite monomers are commercially available from AM Biotechnologies and this unit describes an effective methodology for solid-phase synthesis, deprotection, and purification of RNAs having PS2 internucleotide linkages. © 2017 by John Wiley & Sons, Inc.
Copyright © 2017 John Wiley & Sons, Inc.

Entities:  

Keywords:  PS2-RNA; phosphorodithioate oligoribonucleotide; solid-phase synthesis; sulfur-modified oligonucleotide; thiophosphoramidite

Mesh:

Substances:

Year:  2017        PMID: 28921494      PMCID: PMC5657504          DOI: 10.1002/cpnc.40

Source DB:  PubMed          Journal:  Curr Protoc Nucleic Acid Chem        ISSN: 1934-9270


  37 in total

1.  Nucleic Acid Selection and the Challenge of Combinatorial Chemistry.

Authors:  Scott E. Osborne; Andrew D. Ellington
Journal:  Chem Rev       Date:  1997-04-01       Impact factor: 60.622

2.  Delivery of double-stranded DNA thioaptamers into HIV-1 infected cells for antiviral activity.

Authors:  Monique R Ferguson; Daniel R Rojo; Anoma Somasunderam; Varatharasa Thiviyanathan; Bettye D Ridley; Xianbin Yang; David G Gorenstein
Journal:  Biochem Biophys Res Commun       Date:  2006-04-17       Impact factor: 3.575

3.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.

Authors:  C Tuerk; L Gold
Journal:  Science       Date:  1990-08-03       Impact factor: 47.728

4.  Strategies for the discovery of therapeutic aptamers.

Authors:  Xianbin Yang; Na Li; David G Gorenstein
Journal:  Expert Opin Drug Discov       Date:  2011-01       Impact factor: 6.098

5.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

6.  Thioaptamer decoy targeting of AP-1 proteins influences cytokine expression and the outcome of arenavirus infections.

Authors:  Susan M Fennewald; Erin P Scott; Lihong Zhang; Xianbin Yang; Judith F Aronson; David G Gorenstein; Bruce A Luxon; Robert E Shope; David W C Beasley; Alan D T Barrett; Norbert K Herzog
Journal:  J Gen Virol       Date:  2007-03       Impact factor: 3.891

7.  Gene silencing activity of siRNA molecules containing phosphorodithioate substitutions.

Authors:  Xianbin Yang; Malgorzata Sierant; Magdalena Janicka; Lukasz Peczek; Carlos Martinez; Tom Hassell; Na Li; Xin Li; Tianzhi Wang; Barbara Nawrot
Journal:  ACS Chem Biol       Date:  2012-04-26       Impact factor: 5.100

Review 8.  Pervasive roles of microRNAs in cardiovascular biology.

Authors:  Eric M Small; Eric N Olson
Journal:  Nature       Date:  2011-01-20       Impact factor: 49.962

9.  A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity.

Authors:  Jesper B Bramsen; Maria B Laursen; Anne F Nielsen; Thomas B Hansen; Claus Bus; Niels Langkjaer; B Ravindra Babu; Torben Højland; Mikhail Abramov; Arthur Van Aerschot; Dalibor Odadzic; Romualdas Smicius; Jens Haas; Cordula Andree; Jharna Barman; Malgorzata Wenska; Puneet Srivastava; Chuanzheng Zhou; Dmytro Honcharenko; Simone Hess; Elke Müller; Georgii V Bobkov; Sergey N Mikhailov; Eugenio Fava; Thomas F Meyer; Jyoti Chattopadhyaya; Marino Zerial; Joachim W Engels; Piet Herdewijn; Jesper Wengel; Jørgen Kjems
Journal:  Nucleic Acids Res       Date:  2009-03-12       Impact factor: 16.971

10.  Evoking picomolar binding in RNA by a single phosphorodithioate linkage.

Authors:  N Dinuka Abeydeera; Martin Egli; Nehemiah Cox; Karen Mercier; Jonas Nascimento Conde; Pradeep S Pallan; Daniella M Mizurini; Malgorzata Sierant; Fatima-Ezzahra Hibti; Tom Hassell; Tianzhi Wang; Feng-Wu Liu; Hong-Min Liu; Carlos Martinez; Anil K Sood; Terry P Lybrand; Chiraz Frydman; Robson Q Monteiro; Richard H Gomer; Barbara Nawrot; Xianbin Yang
Journal:  Nucleic Acids Res       Date:  2016-08-26       Impact factor: 16.971

View more
  3 in total

1.  Crystal structures of thrombin in complex with chemically modified thrombin DNA aptamers reveal the origins of enhanced affinity.

Authors:  Rafal Dolot; Curtis H Lam; Malgorzata Sierant; Qiang Zhao; Feng-Wu Liu; Barbara Nawrot; Martin Egli; Xianbin Yang
Journal:  Nucleic Acids Res       Date:  2018-05-18       Impact factor: 16.971

2.  Investigating discovery strategies and pharmacological properties of stereodefined phosphorodithioate LNA gapmers.

Authors:  Jörg Duschmalé; Adrian Schäublin; Erik Funder; Steffen Schmidt; Łukasz J Kiełpiński; Helle Nymark; Klaus Jensen; Troels Koch; Martina Duschmalé; Erich Koller; Marianne Ravn Møller; Simone Schadt; Christophe Husser; Andreas Brink; Sabine Sewing; Tanja Minz; Jesper Wengel; Konrad Bleicher; Meiling Li
Journal:  Mol Ther Nucleic Acids       Date:  2022-06-22       Impact factor: 10.183

3.  Synthesis of 5'-Thiamine-Capped RNA.

Authors:  Marvin Möhler; Katharina Höfer; Andres Jäschke
Journal:  Molecules       Date:  2020-11-24       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.